---
title: Fluid ORiented Therapy for yoUNg Asa 1patients
nct_id: NCT03090399
overall_status: COMPLETED
phase: NA
sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
study_type: INTERVENTIONAL
primary_condition: Hemodynamics
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03090399.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03090399"
ct_last_update_post_date: 2017-03-24
last_seen_at: "2026-05-12T07:24:36.613Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Fluid ORiented Therapy for yoUNg Asa 1patients

**Official Title:** Effects of the Goal-directed Fluid Therapy on ASA 1 Patients Scheduled for Intensive Debulking Surgery

**NCT ID:** [NCT03090399](https://clinicaltrials.gov/study/NCT03090399)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 60
- **Lead Sponsor:** Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- **Conditions:** Hemodynamics
- **Start Date:** 2012-01
- **Completion Date:** 2017-01
- **CT.gov Last Update:** 2017-03-24

## Brief Summary

In this retrospective analysis investigators will study the effects of using a minimally invasive hemodynamic monitoring (FloTrac-Edwards) on postoperative outcomes. Participants will compare a control group to a case group; in both groups ASA 1 patients suffering from advanced ovarian cancer underwent radical cytoreductive surgery. In case group hemodynamic was managed by using the FloTrac system; in the control group a standard hemodynamic monitoring was used.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 65 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* ASA 1

Exclusion Criteria:

* cardiac diseases
* pulmonary diseases
* renal diseases
* metabolic disorders
```

## Arms

- **control group** (NO_INTERVENTION) — patients in which standard fluid administration was applied
- **case group** (ACTIVE_COMPARATOR) — patients in which fluids were administered according to FloTrac parameters

## Interventions

- **FloTrac** (DEVICE) — For patients belonging to case group a Pulse Contour Analysis was adopted for optimize fluid administration

## Primary Outcomes

- **prevalence of complications** _(time frame: up to 30 days)_

## Secondary Outcomes

- **days of hospitalization** _(time frame: up to 12 weeks)_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03090399.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03090399*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*